Terbinafine HCl 250 mg Tablet Formulations Under Non-Fasting Conditions
Condition: Healthy
Intervention: Terbinafine HCl 250mg tablets; Lamisil® 250 mg Tablets
Intervention description: 1 x 250 mg; 1 x 250 mg
Intervention MeSH terms: Terbinafine
Phase: Phase 1
Study type: Interventional
Primary purpose: Other
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Enrollment: 22.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Bioequivalence; Healthy Subjects

Summary:

      The Purpose of this study os to evaluate the relative bioavailability of the test formulation
      of terbinafine tablets with an already marketed reference formulation Lamisil® (Novartis
      Pharmaceuticals), under post-prandial conditions in healthy, non-tobacco using male and
      female adult subjects.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Males and females, 18 years or older inclusive with a body mass index (BMI) of 30 or
             less.

          -  Good health as determined by lack of clinically significant abnormalities in health
             assessments performed at screening.

          -  Signed and dated informed consent form, which meets all criteria of current FDA
             regulations

          -  If female and of child bearing potential subjects must be prepared to abstain from
             sexual intercourse or use a reliable barrier method of contraception (e.g. condom,
             IUD) during the duration of the study. Female subjects who have used oral
             contraceptives within 14 days or injected hormonal contraceptives within 180 days of
             dosing will not be allowed to participate.

        Exclusion Criteria:

          -  If female, pregnant, lactating or likely to become pregnant during the study.

          -  History of allergy or sensitivity to terbinafine, or history of any drug
             hypersensitivity or intolerance which, in the opinion of the Investigator, would
             compromise the safety of the subject or the study.

          -  Significant history or current evidence of chronic evidence of chronic infectious
             disease, system disorder ot organ dysfunction.

          -  Presence of gastrointestinal disease ot history of malabsorption within the last year.

          -  History of psychiatric disorders occuring within the last two years that required
             hospitalization or medication.

          -  Presence of a medical condition requiring regular treatment with prescription drugs.

          -  Use of pharmacologic agents known to significantly induce or inhibit drug-metabolizing
             enzymes. within 30 days prior to dosing.

          -  Receipt of any drug as part of a research study within 30 days prior to dosing.

          -  Drug or alcohol addition requiring treatment in the past 12 months.

          -  Donation or significant loss of whole blood (480 ml or more) within 30 days or plasma
             within 14 days prior to dosing.

          -  Positive test results for drug of abuse at screening.

          -  Tobacco user within 90 days of the first study dose.

          -  Unable, or unwilling to tolerate multiple venipunctures.